Literature DB >> 15194203

Substitutes for tobacco smoking: a behavioral economic analysis of nicotine gum, denicotinized cigarettes, and nicotine-containing cigarettes.

Matthew W Johnson1, Warren K Bickel, Ari P Kirshenbaum.   

Abstract

Both pharmacological and nonpharmacological stimuli may be responsible for the reinforcement and maintenance of tobacco smoking. The present study examined the self-administration of nicotine gum, denicotinized cigarettes, and nicotine-containing cigarettes utilizing a behavioral economic design in order to investigate the pharmacological and nonpharmacological aspects of cigarette smoking. Cigarette-deprived, dependent smokers worked for cigarette puffs and nicotine gum in daily operant sessions. In one phase, nicotine-containing cigarettes were available at increasing unit prices across sessions. Three phases replicated these sessions with nicotine gum, denicotinized cigarettes, or both, concurrently available at a constant unit price. As nicotine-containing cigarette unit price increased, consumption decreased. However, as nicotine-containing cigarette unit price increased, nicotine gum and denicotinized cigarette consumption increased. Consumption of nicotine gum, but not denicotinized cigarettes, diminished when all three reinforcers were concurrently available. Concurrently available denicotinized cigarettes, but not nicotine gum, caused a statistically significant reduction in nicotine-containing cigarette consumption. In another phase, denicotinized cigarettes were available at increasing unit prices across sessions while nicotine gum was concurrently available at a constant unit price. This phase demonstrated that nicotine content had no reliable effect on cigarette or nicotine gum consumption. These results suggest that denicotinized cigarettes are a more effective alternative reinforcer than nicotine gum, indicating that nonpharmacological stimuli of smoking merit attention in smoking cessation treatment. Furthermore, these findings indicate that alternative reinforcement would be most effective in smoking cessation treatment when combined with high prices for cigarettes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15194203     DOI: 10.1016/j.drugalcdep.2003.12.012

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  60 in total

1.  Validation of a behavioral economic purchase task for assessing drug abuse liability.

Authors:  James MacKillop; Nicholas I Goldenson; Matthew G Kirkpatrick; Adam M Leventhal
Journal:  Addict Biol       Date:  2018-01-05       Impact factor: 4.280

2.  A preliminary analysis of adaptive responding under open and closed economies.

Authors:  Henry S Roane; Nathan A Call; Terry S Falcomata
Journal:  J Appl Behav Anal       Date:  2005

Review 3.  Medication screening for smoking cessation: a proposal for new methodologies.

Authors:  Kenneth A Perkins; Maxine Stitzer; Caryn Lerman
Journal:  Psychopharmacology (Berl)       Date:  2005-09-15       Impact factor: 4.530

4.  Expectancy and pharmacology influence the subjective effects of nicotine in a balanced-placebo design.

Authors:  William L Kelemen; Farnaz Kaighobadi
Journal:  Exp Clin Psychopharmacol       Date:  2007-02       Impact factor: 3.157

5.  Tests of behavioral-economic assessments of relative reinforcer efficacy II: economic complements.

Authors:  Gregory J Madden; John R Smethells; Eric E Ewan; Steven R Hursh
Journal:  J Exp Anal Behav       Date:  2007-11       Impact factor: 2.468

6.  Tests of behavioral-economic assessments of relative reinforcer efficacy: economic substitutes.

Authors:  Gregory J Madden; John R Smethells; Eric E Ewan; Steven R Hursh
Journal:  J Exp Anal Behav       Date:  2007-03       Impact factor: 2.468

7.  Demand curves for hypothetical cocaine in cocaine-dependent individuals.

Authors:  Natalie R Bruner; Matthew W Johnson
Journal:  Psychopharmacology (Berl)       Date:  2013-11-12       Impact factor: 4.530

Review 8.  Abuse liability assessment of tobacco products including potential reduced exposure products.

Authors:  Lawrence P Carter; Maxine L Stitzer; Jack E Henningfield; Rich J O'Connor; K Michael Cummings; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

Review 9.  Clinical trials methods for evaluation of potential reduced exposure products.

Authors:  Dorothy K Hatsukami; Karen Hanson; Anna Briggs; Mark Parascandola; Jeanine M Genkinger; Richard O'Connor; Peter G Shields
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

10.  Comparative abuse liability of GHB and ethanol in humans.

Authors:  Matthew W Johnson; Roland R Griffiths
Journal:  Exp Clin Psychopharmacol       Date:  2013-02-18       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.